News

12Dec

Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla™ Oncotype DX Genomic Prostate Score® Test.

On the 3^rd of December, Genomic Health, Inc and Biocartis Group NV announced that they have expanded their exclusive collaboration into the field of urology with the development of an in vitro diagnostic (IVD) version* of the Oncotype DX Genomic Prostate Score® (GPS™) Test on Biocartis’ Idylla™ platform and potentially additional cancer tests that can be performed locally by laboratory partners and in hospitals around the world.

biocartis, genomic health, idylla

18Sep

Molecular

New Idylla NRAS Mutation Test (CE-IVD)

Directly on 1 FFPE tissue section
Detecting 18 relevant mutations

biocartis, braf, gene, idylla, mutation test, nras

18Sep

Molecular

Idylla NRAS-BRAF Mutation Test receives CE-marking

Idylla™ offers complete CE-marked RAS testing for metastatic CRC.

biocartis, braf, idylla, mutation, nras

18Sep

Molecular

Biocartis launches second liquid biopsy assay

Biocartis, an innovative molecular diagnostics company, today announces the launch of its second liquid biopsy assay, the Idylla™ ctKRAS Mutation Assay (Research Use Only, RUO), which was developed in partnership with the leading science and technology company Merck¹ on Biocartis’ molecular diagnostics platform Idylla™.

biocartis, idylla, KRAS, liquid biopsy assay, merck, mutation

18Sep

Molecular

Idylla EGFR Mutation Assay

Biocartis is pleased to add a new Idylla EGFR (Epidermal Growth Factor Receptor) Mutation Assay (Research Use Only) to their core oncology menu, that now covers most known and used oncology biomarkers.

assay, biocartis, EGFR, idylla, molecular

18Sep

Molecular

Idylla platform – real-time PCR based molecular diagnostics system

Idylla™, Biocartis’ fully automated, real-time PCR based molecular diagnostics system, is designed to offer fast and easy access to clinical molecular diagnostic information, anywhere and anytime.

biocartis, braf, DNA, idylla, molecular, PCR, RNA

18Sep

Molecular

Biocartis Idylla BRAF Mutation Test

Introducing Biocartis Idylla – BRAF molecular results in as little as 90 minutes.

About 50 percent of all melanomas harbor mutations in the BRAF oncogene. Idylla™ BRAF Mutation Test detects BRAF mutations directly from FFPE tissue sections in 90 minutes with less than 2 minutes hands-on time.

biocartis, braf, ffpe, idylla, molecular, mutation, tissue

06Sep

Molecular

Study Reviewing 2,500 Performed Idylla Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods

Press Release: Mechelen, Belgium, 27 June 2018

biocartis, braf, cancer, EGFR, idylla, KRAS, next generation sequencing, NGS, nras, tumour

29Aug

Molecular

Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy

PRESS RELEASE: 28 August 2018

Mechelen, Belgium, 28 August 2018 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has obtained exclusive worldwide license rights for highly innovative EGFR ectodomain mutations that have shown to determine response to targeted therapy for patients with metastatic colorectal cancer¹ (mCRC).

biocartis, colorectal cancer, ectodomain mutations, EGFR, idylla, liquid biopsy, oncology